Affiliation:
1. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Abstract
AbstractThe incidence of intrahepatic cholangiocarcinoma (ICC) has been increasing in recent years and now represents the second most common primary hepatic cancer in the United States. The prognosis is dismal without surgical resection. In patients ineligible to receive curative treatments, locoregional therapies represent a diverse array of techniques that can stabilize or reverse tumor progression to improve overall survival and reduce tumor-related symptoms. Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have been demonstrated to be efficacious methods for this patient population. Deciding between these two options is challenging. This article reviews the differences in patient selection, preprocedural evaluation, financial considerations and availability, quality of life, and rates of complications and overall survival.
Subject
Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. New perspectives in biliary tract cancers;ESMO Gastrointestinal Oncology;2024-09
2. Cholangiocarcinoma;Surgical Clinics of North America;2024-05
3. Maligne Tumoren der Gallengänge und der Gallenblase;Therapie-Handbuch - Onkologie und Hämatologie;2024
4. Maligne Tumoren der Gallengänge und der Gallenblase;Therapie-Handbuch - Gastroenterologie und Hepatologie;2024
5. Unresectable intrahepatic cholangiocarcinoma: TARE or TACE, which one to choose?;Frontiers in Gastroenterology;2023-10-10